Analyst Arthur He CFA from H.C. Wainwright reiterated a Buy rating on Nektar Therapeutics and keeping the price target at $120.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arthur He CFA has given his Buy rating due to a combination of factors including upcoming catalysts and financial performance. Nektar Therapeutics is expected to report topline data from its REZOLVE-AA study in December, which could significantly impact the stock. This study evaluates the treatment rezpeg for alopecia areata and could be a major driver of future revenue, with projections of $306 million by 2035.
Additionally, positive results from the REZOLVE-AD study for atopic dermatitis have been announced, with further data expected in the second half of 2025. This could provide further insights into the drug’s efficacy and support its potential market impact. Financially, Nektar reported better-than-expected revenue for the second quarter of 2025, and with a strong cash position, the company appears well-positioned to fund its operations and continue its development programs.
According to TipRanks, He CFA is a 4-star analyst with an average return of 17.9% and a 50.00% success rate. He CFA covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Solid Biosciences, and Prime Medicine, Inc..